

From Novel Science to Clinical Development: Stories from Small Biotechs



CANCER
PROGRESS
by Defined Health

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth
unconventional insight



From Novel Science to Clinical Development: Stories from Small Biotechs

Moderator:


Jeremy Goldberg, Advisor, Torrey Partners

Panelists:

- *Briggs Morrison, MD, Chief Executive Officer, Syndax Pharmaceuticals, Inc.*
- *Christian Zahnd, PhD, Chief Executive Officer, Molecular Partners AG*
- *Gayle M. Mills, MBA, Chief Business Officer, Symphogen*
- *Gisela M. Schwab, MD, President, Product Development & Medical Affairs and Chief Medical Officer, Exelixis, Inc.*
- *Armand Girard, MBA, VP, Corporate Development, GlycoMimetics, Inc.*

40% of All New Oncology Drugs Approved from 2013-15 Originated in Small Biotechs

Number of Launched Drugs Approved 2013-2015




Adis R&D Insight, EvaluatePharma

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth
unconventional insight



How Bad is “Bad” Biotech Financing Environment ?



The NASDAQ Biotechnology Index is down 34% since its peak last July. We are in the second worst bear market in 35 years.

Torrey Partners, March 2016


Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth
 unconventional insight



Oncology represents over 1/4 of overall pipeline agents

Number of Pipeline Agents Per Top Therapeutic Area* Preclinical - Marketed



*Agents may be double-counted in multiple categories
Categories shown have 1000+ pipeline agents

Cortellis

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016


DefinedHealth
unconventional insight

THERAPEUTIC INSIGHT
by Defined Health

CANCER PROGRESS
by Defined Health

Over $\frac{3}{4}$ of Industry-Funded IO Combination Trials are Sponsored by Major Pharma Players

Number of IO Combo Trials Sponsored by Major Pharma Players



Clinicaltrials.gov - November 2015

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth
unconventional insight



From Novel Science to Clinical Development: Stories from Small Biotechs

Panelists:

- *Briggs Morrison, MD*, Syndax Pharmaceuticals, Inc.
- *Christian Zahnd, PhD*, Molecular Partners AG
- *Gayle M. Mills, MBA*, Symphogen
- *Gisela M. Schwab, MD*, Exelixis, Inc.
- *Armand Girard, MBA*, GlycoMimetics, Inc.



Moderator:

- *Jeremy Goldberg*, Torrey Partners

